BioPharma Resources

Drug Trial Radar · NCT04294667

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

Last checked: Nov 19, 2026Latest source record: May 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 321 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

321

Actual

Start

Aug 12, 2020

Primary completion

May 22, 2024

Study completion Jun 4, 2024

Sponsor

Lead sponsor
UCB Biopharma SRLUCB
Sponsor type
Industry
First posted
Mar 4, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.

Conditions

  • Systemic Lupus Erythematosus

Interventions

  • DZPDrug

    Subjects will receive dapirolizumab pegol at prespecified time-points.

  • PlaceboOther

    Subjects will receive placebo at prespecified time-points.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Achievement of BILAG 2004-based Composite Lupus Assessment (BICLA) Response at Week 48Time frame: Week 48

Locations

177 sites in 25 countries. Site status is shown where the registry gives one.

  • Sl0043 50140

    Birmingham, Alabama

  • Sl0043 50052

    Phoenix, Arizona

  • Sl0043 50328

    Tucson, Arizona

  • Sl0043 50383

    Beverly Hills, California

  • Sl0043 50257

    La Jolla, California

  • Sl0043 50275

    La Palma, California

  • Sl0043 50378

    Loma Linda, California

  • Sl0043 50258

    Los Angeles, California

  • Sl0043 50340

    Orange, California

  • Sl0043 50331

    Poway, California

  • Sl0043 50377

    San Diego, California

  • Sl0043 50316

    San Leandro, California

  • Sl0043 50339

    Denver, Colorado

  • Sl0043 50367

    New Haven, Connecticut

  • Sl0043 50341

    Washington D.C., District of Columbia

  • Sl0043 50239

    Brandon, Florida

  • Sl0043 50362

    Gainesville, Florida

  • Sl0043 50122

    Miami, Florida

  • Sl0043 50059

    Ormond Beach, Florida

  • Sl0043 50324

    Plantation, Florida

  • Sl0043 50329

    Tampa, Florida

  • Sl0043 50283

    Tampa, Florida

  • Sl0043 50368

    Atlanta, Georgia

  • Sl0043 50382

    Atlanta, Georgia

  • Sl0043 50240

    Idaho Falls, Idaho

  • Sl0043 50310

    Chicago, Illinois

  • Sl0043 50360

    Skokie, Illinois

  • Sl0043 50474

    Hopkinsville, Kentucky

  • Sl0043 50285

    Lake Charles, Louisiana

  • Sl0043 50288

    Cumberland, Maryland

  • Sl0043 50015

    Hagerstown, Maryland

  • Sl0043 50219

    Detroit, Michigan

  • Sl0043 50333

    Grand Blanc, Michigan

  • Sl0043 50273

    Las Vegas, Nevada

  • Sl0043 50010

    Brooklyn, New York

  • Sl0043 50366

    Canton, New York

  • Sl0043 50266

    Great Neck, New York

  • Sl0043 50264

    Manhasset, New York

  • Sl0043 50077

    New York, New York

  • Sl0043 50334

    New York, New York

Showing 40 of 177 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.